Recently, Guangzhou Zhiyi Biotech announced that it has received a funding approval from Guangdong Technology Financial Group and Ai Rui Investment for nearly CNY 100 million.The funds are mainly used for the clinical development of the company’s new drug pipeline, especially the Phase III clinical trial of SK08.

Zhiyi Biotechnology is an original new drug research and development enterprise based in China and facing the world in the clinical development stage. It is a leader in live biopharmaceutical products (LBPs) in China and has a complete technology and industrialization platform from strain discovery to LBP development. SK08, independently developed by the company, uses a new generation of probiotics and is the fastest progressing LBP drug in China. Phase III clinical research on IBS-D (Irritable Bowel Syndrome) is currently underway. Another original SK10 for CID has been completed in Phase I clinical trials in the United States.

Zhiyi Biotech Raised Nearly CNY100 Million C Round of Financing to Accelerate the Phase III clinical research